Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4
Rizk, Hanan H; Prof. Hamdy, Nadia M.; Al-Ansari, Nadia L; El-Mesallamy, Hala O;
Abstract
Egypt has the highest prevalence of a difficult to treat chronic hepatitis C virus (HCV), genotype 4. Pretreatment factors could guide individualization of therapy which aids in treatment optimization and interleukin IL28B gene polymorphism has been shown to closely relate to HCV treatment response. Polymorphisms in genes encoding inhibitors of T-cell response, which have role in disease progression as Programmed Cell Death 1 (PD-1), and Cytotoxic T-Lymphocytes Antigen-4 (CTLA-4), could be candidate markers predicting treatment response.
Other data
| Title | Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4 | Authors | Rizk, Hanan H; Prof. Hamdy, Nadia M. ; Al-Ansari, Nadia L; El-Mesallamy, Hala O | Issue Date | 2016 | Journal | PloS one | ISSN | 1932-6203 | DOI | 10.1371/journal.pone.0153895 | PubMed ID | 27100663 | Scopus ID | 2-s2.0-84964869159 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.